Compare · EPRX vs NVCN
EPRX vs NVCN
Side-by-side comparison of Eupraxia Pharmaceuticals Inc. (EPRX) and Neovasc Inc. (NVCN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EPRX and NVCN operate in Pharmaceuticals and Biotechnology (Health Care), so they compete in similar markets.
- EPRX is the larger of the two at $489.0M, about 17.6x NVCN ($27.8M).
- EPRX has hit the wire 9 times in the past 4 weeks while NVCN has been quiet.
- EPRX has more recent analyst coverage (8 ratings vs 0 for NVCN).
- Company
- Eupraxia Pharmaceuticals Inc.
- Neovasc Inc.
- Price
- -
- -
- Market cap
- $489.0M
- $27.8M
- 1M return
- +21.43%
- -
- 1Y return
- +43.04%
- -
- Industry
- Pharmaceuticals and Biotechnology
- Pharmaceuticals and Biotechnology
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 9
- 0
- Recent ratings
- 8
- 0
NVCN
Neovasc Inc.
Neovasc Inc., a specialty medical device company, develops, manufactures, and markets medical devices for cardiovascular marketplace in Europe, Canada, the United States, and internationally. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.
Latest EPRX
- SEC Form EFFECT filed by Eupraxia Pharmaceuticals Inc.
- Amendment: SEC Form F-10/A filed by Eupraxia Pharmaceuticals Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Eupraxia Pharmaceuticals Inc.
- SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.
- Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Painful Swallowing) in Eosinophilic Esophagitis Patients
- SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.
- Eupraxia Pharmaceuticals Reports Second Quarter 2026 Financial Results
- SEC Form F-X filed by Eupraxia Pharmaceuticals Inc.
- SEC Form F-10 filed by Eupraxia Pharmaceuticals Inc.
- SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.
Latest NVCN
- Volato Announces Changes to Board Composition
- SEC Form EFFECT filed by Neovasc Inc.
- SEC Form 15F-12B filed by Neovasc Inc.
- SEC Form 6-K filed by Neovasc Inc.
- SEC Form 6-K filed by Neovasc Inc.
- SEC Form RW filed by Neovasc Inc.
- SEC Form F-10POS filed by Neovasc Inc.
- SEC Form POS AM filed by Neovasc Inc.
- SEC Form S-8 POS filed by Neovasc Inc.
- SEC Form 25-NSE filed by Neovasc Inc.